Key facts
- · Type: Amendment first sale 2022-02-17 · Amount sold: $71K · Total offering: $71K · SEC filing
- · Type: Filing · SEC filing
- · Type: Filing · SEC filing
- · Type: Amendment · SEC filing
- · Type: New offering first sale 2022-04-15 · Amount sold: $3M · Total offering: $6M · SEC filing
Is Avicenna Biosciences, Inc. a real, registered company?
Avicenna Biosciences, Inc. is a registered filer with the SEC (CIK 1824034) and has filed since 2022-10-27. 6 filings are on record, the latest on 2025-10-30.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has Avicenna Biosciences, Inc. raised?
Its new offerings report $3M sold across 1 offering, as its own filings state.
Run the free check on Avicenna Biosciences, Inc. →
DURHAM, NORTH CAROLINA
Biotechnology
6
$3M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2025-10-30 | Amendment first sale 2022-02-17 | $71K | $71K | SEC filing |
| 2024-07-16 | Filing | — | — | SEC filing |
| 2024-02-23 | Filing | — | — | SEC filing |
| 2023-03-22 | Amendment | — | — | SEC filing |
| 2022-12-30 | New offering first sale 2022-04-15 | $3M | $6M | details · SEC filing |
| 2022-10-27 | Filing | — | — | SEC filing |
Keep reading
More on Avicenna Biosciences, Inc. and the records around it.
Avicenna Biosciences, Inc. elsewhere on the record
- Form D filing Dec 2022
Watch Avicenna Biosciences, Inc.
Get an email when Avicenna Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Avicenna Biosciences, Inc.?
Who to contact
- Christopher Meldrum — Executive Officer, Director
- Thomas Kaiser — Executive Officer, Director
- Pieter Burger — Executive Officer, Director
- John Hamer — Director
- Dennis Langer — Director
- Round: Form D/A (amended) filed 2025-10-30
- Amount sold: $71K
- Industry: Biotechnology
- Based: DURHAM, NORTH CAROLINA
People listed
- Christopher Meldrum — Executive Officer, Director
- Thomas Kaiser — Executive Officer, Director
- Pieter Burger — Executive Officer, Director
- John Hamer — Director
- Dennis Langer — Director
- Filing: Form D/A (amended) filed 2025-10-30
- Amount sold: $71K
- Industry group: Biotechnology
- Based: DURHAM, NORTH CAROLINA
- Entity type: Corporation
We'll show it in your MentionFox inbox when Avicenna Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Avicenna Biosciences, Inc. →Want the whole picture on Avicenna Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Avicenna Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avicenna Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Avicenna Biosciences, Inc.'s own filings with the SEC. The people those filings name are on the team page.